Wikipedia -WSS

Wikipedia

author：comprehensive 2025-10-02 13:01:29 - browse：8

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

hotspot

WSS

Stop the failed accountable care organization experiment

A new approach to psychiatric drug development

Medicare drug price negotiation continues, as pharma counteroffers

Longer MASH drug regimen improved liver, Akero study finds

Orchard's therapy for neuron disease in children wins FDA approval

Florida health officials providing scant details on measles cases

hotspot

Wikipedia

Wikipedia

Anesthesiologist group: stop taking Ozempic before surgery

State of the Union pitch: Bigger Medicare drug price negotiations

Wildfire smoke exposes gaps in outdoor worker protections

State of the Union pitch: Bigger Medicare drug price negotiations

Virginia high school admissions case could be legal follow

Physicians and social media: If you see something, say something?

Medical records are filled with copy

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Dobbs anniversary: the lost opportunity of abortion as health care

Orchard's therapy for neuron disease in children wins FDA approval

hotspot

Plastic surgeons increase patient psychiatric screenings

Families look for replacement for GSK asthma drug Flovent

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Health AI adoption puts security, privacy startups on investors' radar

Change Healthcare: What is it, why does its cyberattack matter?

Orchard's therapy for neuron disease in children wins FDA approval

entertainment

explore

hotspot

hotspot